HEALTH Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy Tuesday, April 7, 2026 · climb bio, inc. Advertisement Read Original Article → Related Dispatches [US] · Jul 30 FTC, Hims and Hers, Ebola vaccine: Morning Rounds [CA] · Jul 30 Leaked health care report shows Lloydminster services 'struggling to keep up': Sask. NDP [US] · Jul 30 STAT+: Tracking the FDA expert review of Replimune’s melanoma treatment